line 24, change "(SEQ ID NO: 20)" to --(SEQ ID NO: 19)--;

line 25, delete "(SEQ ID NO: 21)";

line 33, change "(SEQ ID NO: 22)" to --(SEQ ID NO: 20)--;

line 34, delete "(SEQ ID NO: 23)";

Page 93,   line 14, change "(SEQ ID NO: 24)" to --(SEQ ID NO: 21)--;

                line 16, change "(SEQ ID NO: 25)" to --(SEQ ID NO: 22)--;

Page 99,   line 29, change "(SEQ ID NO: 26)" to --(SEQ ID NO: 23)--;

                line 31, change "(SEQ ID NO: 27)" to --(SEQ ID NO: 24)--;

                line 33, change "(SEQ ID NO: 28)" to --(SEQ ID NO: 25)--;

                line 35, change "(SEQ ID NO: 29)" to --(SEQ ID NO: 26)--;

                line 36, change "(SEQ ID NO: 30)" to --(SEQ ID NO: 27)--;

Page 100,   line 1, change "(SEQ ID NO: 31)" to --(SEQ ID NO: 28)--; and

                line 3, change "(SEQ ID NO: 32)" to --(SEQ ID NO: 29)--.

IN THE CLAIMS

Please cancel Claims 3, 38, and 39.

Please amend the claims as follows:

1.   (Twice Amended) An isolated substantially homogeneous human *mpl* ligand wherein the amino acid sequence of the ligand consists of amino acid residues 1 to X of **Fig. 8**, where X is selected from the group consisting of residues 153-332.

9.   (Twice Amended) An isolated substantially homogeneous *mpl* ligand [encoded by a nucleic acid having a sequence that hybridizes under stringent conditions to the nucleic acid molecules encoding] consisting of residues 1 to X of **Fig. 8** where X is residue 153.

32.   (Amended) The *mpl* ligand of Claim 1 where X is selected from the group consisting of residues 153-166.